Listen: Novavax’s CEO promises a turnaround & how Lilly roiled the obesity market
Can Novavax finally get it right? What's a "triple-G" drug? And is Novo Nordisk losing ground? Find out on the new episode of "The Readout LOUD."
Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.
What's Your Reaction?
